Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.19
(4.07%)
SEK 0.19
(4.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -388.17 Million SEK | -125.39% |
| 2022 | -172.22 Million SEK | 9.83% |
| 2021 | -191.01 Million SEK | 15.78% |
| 2020 | -226.79 Million SEK | -35.42% |
| 2019 | -167.47 Million SEK | -1165.29% |
| 2018 | -13.23 Million SEK | 70.54% |
| 2017 | -44.93 Million SEK | -34.99% |
| 2016 | -33.28 Million SEK | -181.04% |
| 2015 | -11.84 Million SEK | -360.53% |
| 2014 | -2.57 Million SEK | -22.06% |
| 2013 | -2.1 Million SEK | -152.65% |
| 2012 | -834.04 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -97.4 Million SEK | 38.17% |
| 2024 Q2 | -70.5 Million SEK | 27.62% |
| 2024 Q3 | -45.11 Million SEK | 36.01% |
| 2023 Q3 | -81.23 Million SEK | 10.75% |
| 2023 Q4 | -157.53 Million SEK | -93.93% |
| 2023 Q2 | -91.01 Million SEK | -55.92% |
| 2023 FY | -388.17 Million SEK | -125.39% |
| 2023 Q1 | -58.37 Million SEK | 3.43% |
| 2022 Q2 | -33.77 Million SEK | 6.5% |
| 2022 Q4 | -60.44 Million SEK | -44.32% |
| 2022 FY | -172.22 Million SEK | 9.83% |
| 2022 Q1 | -36.12 Million SEK | -11.24% |
| 2022 Q3 | -41.88 Million SEK | -24.01% |
| 2021 Q2 | -59.16 Million SEK | -15.41% |
| 2021 Q1 | -51.26 Million SEK | 18.69% |
| 2021 FY | -191.01 Million SEK | 15.78% |
| 2021 Q4 | -32.47 Million SEK | 28.59% |
| 2021 Q3 | -45.47 Million SEK | 23.15% |
| 2020 Q2 | -53.39 Million SEK | -9.23% |
| 2020 FY | -226.79 Million SEK | -35.42% |
| 2020 Q4 | -63.05 Million SEK | -9.2% |
| 2020 Q3 | -57.74 Million SEK | -8.14% |
| 2020 Q1 | -48.88 Million SEK | 12.59% |
| 2019 Q2 | -44.39 Million SEK | -33.28% |
| 2019 Q3 | -32.39 Million SEK | 27.03% |
| 2019 Q4 | -55.92 Million SEK | -72.62% |
| 2019 FY | -167.47 Million SEK | -1165.29% |
| 2019 Q1 | -33.31 Million SEK | -2.74% |
| 2018 Q3 | 60.09 Million SEK | 287.84% |
| 2018 Q2 | -31.99 Million SEK | -258.83% |
| 2018 Q4 | -32.42 Million SEK | -153.95% |
| 2018 Q1 | -8.91 Million SEK | 53.46% |
| 2018 FY | -13.23 Million SEK | 70.54% |
| 2017 Q4 | -19.15 Million SEK | -110.7% |
| 2017 Q3 | -9.09 Million SEK | 3.15% |
| 2017 Q2 | -9.38 Million SEK | 7.37% |
| 2017 FY | -44.93 Million SEK | -34.99% |
| 2017 Q1 | -10.13 Million SEK | -0.34% |
| 2016 Q2 | -7.55 Million SEK | -36.65% |
| 2016 Q3 | -10.1 Million SEK | -33.67% |
| 2016 Q1 | -5.53 Million SEK | -3.74% |
| 2016 Q4 | -10.09 Million SEK | 0.02% |
| 2016 FY | -33.28 Million SEK | -181.04% |
| 2015 Q2 | -1.33 Million SEK | -23.24% |
| 2015 Q1 | -1.08 Million SEK | 17.9% |
| 2015 FY | -11.84 Million SEK | -360.53% |
| 2015 Q4 | -5.33 Million SEK | -30.07% |
| 2015 Q3 | -4.09 Million SEK | -207.41% |
| 2014 Q3 | -616.08 Thousand SEK | 0.0% |
| 2014 Q4 | -1.31 Million SEK | -113.89% |
| 2014 FY | -2.57 Million SEK | -22.06% |
| 2013 FY | -2.1 Million SEK | -152.65% |
| 2012 FY | -834.04 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcouSort AB (publ) | -17.08 Million SEK | -2171.473% |
| Alzinova AB (publ) | -16.48 Million SEK | -2255.413% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -2925.974% |
| BioArctic AB (publ) | 229.24 Million SEK | 269.323% |
| Camurus AB (publ) | 431.44 Million SEK | 189.971% |
| Kancera AB (publ) | -64.88 Million SEK | -498.209% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 7307.055% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | -24.837% |
| Xintela AB (publ) | -54.08 Million SEK | -617.734% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -2068.922% |
| Active Biotech AB (publ) | -45.8 Million SEK | -747.537% |
| Amniotics AB (publ) | -30.87 Million SEK | -1157.441% |
| Cantargia AB (publ) | -280.02 Million SEK | -38.619% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1740.463% |
| CombiGene AB (publ) | -35.66 Million SEK | -988.371% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -155.629% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -2267.194% |
| Genovis AB (publ.) | 61.5 Million SEK | 731.174% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -242.536% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -947.104% |
| Saniona AB (publ) | -95.81 Million SEK | -305.148% |
| OncoZenge AB (publ) | -15.9 Million SEK | -2341.026% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -56.152% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 16.734% |
| Mendus AB (publ) | -101.61 Million SEK | -281.988% |
| Intervacc AB (publ) | -102.85 Million SEK | -277.408% |
| LIDDS AB (publ) | -40.2 Million SEK | -865.458% |
| Lipum AB (publ) | -37.17 Million SEK | -944.091% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -3100.627% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 3289.843% |
| NextCell Pharma AB | -41.95 Million SEK | -825.104% |
| Simris Alg AB (publ) | -37.3 Million SEK | -940.536% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -819.338% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -1535.304% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -116.051% |
| Ziccum AB (publ) | -21.41 Million SEK | -1712.871% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -88523.744% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -2249.283% |
| Corline Biomedical AB | -1.8 Million SEK | -21357.822% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -118.272% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -583.149% |
| Aptahem AB (publ) | -11.11 Million SEK | -3392.995% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -215.413% |
| Fluicell AB (publ) | -26.55 Million SEK | -1361.821% |
| Biovica International AB (publ) | -124.82 Million SEK | -210.978% |
| Abliva AB (publ) | -95.5 Million SEK | -306.425% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | -18.743% |
| 2cureX AB (publ) | -32.51 Million SEK | -1093.714% |
| I-Tech AB | 20.2 Million SEK | 2021.358% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 53.329% |
| Cyxone AB (publ) | -22.98 Million SEK | -1588.512% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -324.691% |
| Biosergen AB | -27.03 Million SEK | -1335.707% |
| Nanologica AB (publ) | -75.15 Million SEK | -416.481% |
| SynAct Pharma AB | -215.81 Million SEK | -79.867% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -781.128% |
| BioInvent International AB (publ) | -330.3 Million SEK | -17.52% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -55.823% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -3809.08% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -255.183% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -3223.96% |